DK1214061T3 - Anvendelse af docetaxel til behandling af hepatocellulært carcinom - Google Patents

Anvendelse af docetaxel til behandling af hepatocellulært carcinom

Info

Publication number
DK1214061T3
DK1214061T3 DK00964144T DK00964144T DK1214061T3 DK 1214061 T3 DK1214061 T3 DK 1214061T3 DK 00964144 T DK00964144 T DK 00964144T DK 00964144 T DK00964144 T DK 00964144T DK 1214061 T3 DK1214061 T3 DK 1214061T3
Authority
DK
Denmark
Prior art keywords
docetaxel
hepatocellular carcinoma
treatment
mum
paclitaxel
Prior art date
Application number
DK00964144T
Other languages
Danish (da)
English (en)
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Lui
Gar-Yang Chau
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1214061T3 publication Critical patent/DK1214061T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK00964144T 1999-08-31 2000-08-29 Anvendelse af docetaxel til behandling af hepatocellulært carcinom DK1214061T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
DK1214061T3 true DK1214061T3 (da) 2004-11-01

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00964144T DK1214061T3 (da) 1999-08-31 2000-08-29 Anvendelse af docetaxel til behandling af hepatocellulært carcinom

Country Status (34)

Country Link
US (2) US20030158249A1 (de)
EP (1) EP1214061B1 (de)
JP (1) JP4866522B2 (de)
KR (1) KR100670416B1 (de)
CN (1) CN1174748C (de)
AT (1) ATE269700T1 (de)
AU (1) AU777583B2 (de)
BG (1) BG65913B1 (de)
BR (1) BR0013625A (de)
CA (1) CA2382294C (de)
CZ (1) CZ301378B6 (de)
DE (1) DE60011794T2 (de)
DK (1) DK1214061T3 (de)
EA (1) EA004804B1 (de)
EE (1) EE05124B1 (de)
ES (1) ES2218223T3 (de)
GB (1) GB9920548D0 (de)
HK (1) HK1048944B (de)
HR (1) HRP20020171A2 (de)
HU (1) HU228861B1 (de)
IL (2) IL147489A0 (de)
ME (1) ME00624B (de)
MX (1) MXPA02002041A (de)
NO (1) NO328527B1 (de)
NZ (1) NZ517604A (de)
PL (1) PL212612B1 (de)
PT (1) PT1214061E (de)
RS (1) RS50148B (de)
SI (1) SI1214061T1 (de)
SK (1) SK286378B6 (de)
TW (1) TW589180B (de)
UA (1) UA72927C2 (de)
WO (1) WO2001015675A2 (de)
ZA (1) ZA200201408B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
PT1694660E (pt) * 2003-12-12 2009-07-16 Quiral Quimica Do Brasil Processo de preparação de ingredientes farmacêuticos activos (api) anidros e hidratados; composições farmacêuticas estáveis preparadas a partir dos mesmos e utilizações das referidas composições
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
EP1928435B8 (de) 2005-08-31 2019-03-20 Abraxis BioScience, LLC Zusammensetzungen von schwer wasserlöslichen arzneimitteln mit erhöhter stabilität und verfahren zu deren herstellung
TWI429452B (zh) 2005-08-31 2014-03-11 Abraxis Bioscience Llc 包含弱水溶性藥劑及抗微生物劑之組合物
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
WO2009007992A2 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical composition produced by microprecipitation
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2552438B1 (de) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Verfahren zur behandlung von hepatozellenkarzinomen
WO2011139899A2 (en) * 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2016134066A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
SG45369A1 (en) * 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
ATE357214T1 (de) * 1996-12-30 2007-04-15 Battelle Memorial Institute Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
MX337149B (es) * 1997-06-27 2016-02-15 Abraxis Bioscience Llc Nuevas formulaciones de agentes farmacologicos, metodos para su preparacion y metodos para el uso de los mismos.
DE69811689T2 (de) * 1997-09-18 2003-12-18 Janssen Pharmaceutica N.V., Beerse Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1140183A1 (de) * 1998-12-23 2001-10-10 G.D. Searle & Co. Verwendung von einem matrix metalloproteinasmemmer und einem integrinantagonist in der behandlung von neoplasie
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
CA2633268A1 (en) * 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
EE200200087A (et) 2003-04-15
NO20020829D0 (no) 2002-02-20
ES2218223T3 (es) 2004-11-16
EE05124B1 (et) 2009-02-16
EP1214061B1 (de) 2004-06-23
EA200200313A1 (ru) 2002-08-29
KR20020060166A (ko) 2002-07-16
DE60011794D1 (de) 2004-07-29
HK1048944A1 (en) 2003-04-25
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
WO2001015675A3 (en) 2001-09-20
NO328527B1 (no) 2010-03-08
AU777583B2 (en) 2004-10-21
CN1174748C (zh) 2004-11-10
RS50148B (sr) 2009-05-06
PL212612B1 (pl) 2012-10-31
EP1214061A2 (de) 2002-06-19
HK1048944B (zh) 2005-04-22
KR100670416B1 (ko) 2007-01-17
BG65913B1 (bg) 2010-05-31
CA2382294A1 (en) 2001-03-08
US20030158249A1 (en) 2003-08-21
SI1214061T1 (en) 2004-12-31
NZ517604A (en) 2004-04-30
JP4866522B2 (ja) 2012-02-01
US20080045584A1 (en) 2008-02-21
BR0013625A (pt) 2002-05-14
SK286378B6 (sk) 2008-08-05
SK2712002A3 (en) 2002-07-02
BG106460A (bg) 2002-09-30
YU11402A (sh) 2005-07-19
CN1372466A (zh) 2002-10-02
CA2382294C (en) 2008-06-03
MEP7809A (en) 2011-12-20
TW589180B (en) 2004-06-01
JP2003508427A (ja) 2003-03-04
HUP0203197A2 (hu) 2003-01-28
DE60011794T2 (de) 2005-07-14
ME00624B (me) 2011-12-20
IL147489A0 (en) 2002-08-14
CZ301378B6 (cs) 2010-02-03
MXPA02002041A (es) 2002-08-20
WO2001015675A2 (en) 2001-03-08
IL147489A (en) 2006-06-11
GB9920548D0 (en) 1999-11-03
HRP20020171A2 (en) 2004-02-29
PL353198A1 (en) 2003-11-03
NO20020829L (no) 2002-02-20
HU228861B1 (hu) 2013-06-28
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
PT1214061E (pt) 2004-09-30
ZA200201408B (en) 2003-07-30
HUP0203197A3 (en) 2005-01-28
UA72927C2 (uk) 2005-05-16

Similar Documents

Publication Publication Date Title
DK1214061T3 (da) Anvendelse af docetaxel til behandling af hepatocellulært carcinom
DK1411938T3 (da) Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis
EP2261200A3 (de) Modifizierte Formen von pharmakologisch aktiven Agenzien und deren Verwendung
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
RS54185B1 (en) USE OF 24-ORDER
DE60128100D1 (de) Analgetisches arzneimittel
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
DE60229414D1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DK1411970T3 (da) Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia
DE60023321D1 (de) Zusammensetzung gegen Coccidiose
TW200744581A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
DK1355650T3 (da) Kombination af aktive bestanddele, som indeholder alfuzosin og apomorphin